Xvivo Perfusion AB ((XVIPF)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: The clinical study titled Direct Procurement (DP) and Hypothermic Oxygenated Perfusion (HOPE) of Donor Hearts After Circulatory Death (DCD) Using the XVIVO Heart Assist Transport System aims to enhance the utilization of donor hearts from circulatory death. The primary goal is to assess patient survival following the use of the XVIVO Heart Assist Transport System, with secondary objectives focusing on patient outcomes and graft function post-transplant.
Intervention/Treatment: The study tests the XVIVO Heart Assist Transport System, a device designed for the direct procurement and hypothermic oxygenated perfusion of donor hearts from circulatory death. This intervention seeks to improve the viability and function of transplanted hearts.
Study Design: This interventional study employs a single-group model with no masking, focusing on treatment as its primary purpose. It evaluates the effects of the XVIVO Heart Assist Transport System on heart transplant outcomes.
Study Timeline: The study began on June 25, 2024, with its latest update submitted on November 26, 2024. These dates are crucial as they mark the study’s progression and the timeliness of data collection and analysis.
Market Implications: The ongoing study could significantly impact Xvivo Perfusion AB’s stock performance by potentially validating a new application for their heart transport system. Positive results may enhance investor confidence and position the company favorably against competitors in the organ transplant technology sector.
The study is currently recruiting, with further details accessible on the ClinicalTrials portal.